PNC Financial Services Group
ECYT

PNC Financial Services Group’s Endocyte, Inc. Common Stock ECYT Stock Holding History

PNC Financial Services Group’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,260
Closed -$22K – 4294
2018
Q3 		$22K Buy
1,260
+760
+152% +$13K ﹤0.01% 3418
2018
Q2 		$7K Buy
+500
New +$5.93K ﹤0.01% 3786
2016
Q3 		– Sell
-189
Closed -$1K – 4468
2016
Q2 		$1K Sell
189
-7
-4% -$26 ﹤0.01% 4440
2016
Q1 		$1K Buy
196
+7
+4% +$23 ﹤0.01% 4439
2015
Q4 		$1K Hold
189
– – ﹤0.01% 4394
2015
Q3 		$1K Buy
189
+6
+3% +$31 ﹤0.01% 4545
2015
Q2 		$1K Sell
183
-6
-3% -$36 ﹤0.01% 4612
2015
Q1 		$1K Sell
189
-520
-73% -$3K ﹤0.01% 4582
2014
Q4 		$5K Buy
709
+599
+545% +$3.65K ﹤0.01% 3566
2014
Q3 		$1K Hold
110
– – ﹤0.01% 3903
2014
Q2 		$1K Sell
110
-9
-8% -$101 ﹤0.01% 3741
2014
Q1 		$3K Buy
+119
New +$1.73K ﹤0.01% 3428

Other funds holding ECYT

OTC
Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return
CA
Claro Advisors Boston, Massachusetts $953M AUM 24.79% 1-Year Est. Return

PNC Financial Services Group's ECYT Position: Q4 2018 in Review

PNC Financial Services Group sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 1,260 shares — an estimated $22K sold.

PNC Financial Services Group first reported a position in ECYT in Q1 2014 and held it in 12 quarters. The position peaked at $22K in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

  • PNC Financial Services Group reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • PNC Financial Services Group sold 1,260 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $22K.
  • PNC Financial Services Group first reported a position in Endocyte, Inc. Common Stock in Q1 2014 and held it in 12 quarters.
  • PNC Financial Services Group's Endocyte, Inc. Common Stock position peaked at $22K in Q3 2018.
  • 2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on PNC Financial Services Group's 13F filing for Q4 2018, filed 8 Feb 2019.